HIV entry inhibitors

HIV entry inhibitors

A new class of antiretroviral drugs that target the process of entry of HIV into the cell. They include HIV fusion inhibitors and HIV co-receptor antagonists. Enfuvirtide (Fuzeon) was the first entry inhibitor to be developed.
References in periodicals archive ?
Jiang, "Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41," Current Topics in Medicinal Chemistry, vol.
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
"In order to efficiently block intracellular fusion events, the next generation of HIV entry inhibitors must be able to permeate the cell membrane," he added.
All the other products mentioned are called HIV entry inhibitors and block HIV infection.
With a far greater understanding of the HIV cell entry process, we can now envisage HIV entry inhibitors as whole new classes of drugs for the future.
HIV entry inhibitors in early development DRUG NAME CURRENTLY GIVEN COMPANY AMD-070 By mouth Anormed AMD-887 By mouth Anormed PRO-140 By injection or infusion * Progenics BMS-488043 By mouth Bristol-Myers Squibb UK 427,857 By mouth Pfizer SP-01A By mouth Samaritan Pharmaceuticals SCH-D By mouth Schering Plough TNX-355 By infusion Tanox GSK(GW)-873140 By mouth GlaxoSmithKline PRO-542 By injection or infusion * Progenics * infusion is when medication is given directly into a vein over a period of time.
In addition, newer agents with novel mechanisms of action, such as HIV entry inhibitors (which inhibit the three steps of HIV entry: CD4 attachment, chemokine co-receptor binding and membrane fusion) and HIV integrase inhibitors, are also under investigation.
Among the new classes of drugs under study are HJV integrase inhibitors, which block the enzyme that HIV uses to incorporate its genetic material into human DNA, and HIV entry inhibitors, which prevent the virus from entering the cell.
Among the new classes of drugs under study are HIV integrase inhibitors, which block the enzyme that HIV uses to incorporate its genetic material into human DNA, and HIV entry inhibitors, which prevent the virus from entering the cell.
Just as the development of HIV entry inhibitors (see page 6 of this issue) grew from discoveries of the mechanism of viral infection in CD4 T cells, so tot) will other discoveries inspire novel therapeutic strategies, perhaps even a cure.
2DLT, which was created by the combination of the D1D2 domain of the CD4 molecule in the human body and polypeptide HIV entry inhibitor T1144, inhibits and inactivates multiple clades of HIV isolates with high efficiency [71].